Cargando…
Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID-19 compared with standard of care? A literature review
Coronavirus disease 2019 (COVID-19) is global pandemic with various clinical presentations, ranging from cold to sometimes unrecoverable acute respiratory distress syndrome. Although urgently needed, currently there are no specific treatments for COVID-19. Repurposing existing pharmaceuticals to tre...
Autor principal: | Spera, Anna Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995413/ https://www.ncbi.nlm.nih.gov/pubmed/33816150 http://dx.doi.org/10.5501/wjv.v10.i2.53 |
Ejemplares similares
-
Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review
por: Spera, Anna Maria
Publicado: (2022) -
Hepatitis B virus infection reactivation in patients under immunosuppressive therapies: Pathogenesis, screening, prevention and treatment
por: Spera, Anna Maria
Publicado: (2022) -
Hepatocellular carcinoma occurrence in DAA-treated hepatitis C virus patients: Correlated or incidental? A brief review
por: Gigi, Eleni, et al.
Publicado: (2018) -
Kidney transplant from donors with hepatitis B: A challenging treatment option
por: Srisuwarn, Praopilad, et al.
Publicado: (2021) -
Metabolic aspects of hepatitis C virus
por: El-Kassas, Mohamed, et al.
Publicado: (2022)